Looking for top-rated stocks to buy now? Based on recent analyst updates, the three companies below have all earned Strong Buy ratings from Top Wall Street Analysts. Each offers meaningful upside potential, backed by new Buy calls.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
For more ideas, you can explore TipRanks’ Analyst Top Stocks tool, which tracks the latest Buy ratings from top-performing analysts in real time.
Here are today’s top stock picks, according to analysts. Click on any ticker to thoroughly research the stock before you decide whether to add it to your portfolio.
Praxis Precision Medicines (PRAX) – This is a clinical-stage biotech company developing treatments for neurological and psychiatric disorders. Today, H.C. Wainwright analyst Douglas Tsao maintained a Buy rating on the stock and gave a street-high price target of $1,245 per share, citing strong results from its EMBRAVE study in a severe pediatric epilepsy condition. The study showed a 77% reduction in monthly seizures and meaningful seizure-free periods in many patients.
Interestingly, 11 out of the 12 Top Analysts who recently rated PRAX gave it a Buy. Taken together, their 12-month price targets imply an upside of about 115.8%.
Inventiva (IVA) – Inventiva is a clinical-stage biotech company developing oral drugs for liver diseases like NASH. Today, Piper Sandler analyst Yasmeen Rahimi maintained a Buy rating on the stock with a price target of $26 per share, citing growing confidence ahead of its Phase 3 NATiV3 trial readout. In the last three months, all nine Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of 213.09%.
Ovid Therapeutics (OVID) – This is a clinical-stage biotech company developing treatments for rare neurological disorders. Today, Wedbush analyst Laura Chico maintained a Buy rating on the stock with a price target of $7 per share. In the last three months, all seven Top Analysts covering the stock have rated it a Buy. Taken together, their 12-month price targets imply an upside of 128.57%.